摘要
目的探讨p27及CD44V6在卵巢癌中的表达特点及其在判断卵巢癌患者预后中的意义。方法应用免疫组化(二步法)技术对54例卵巢癌组织进行表达检测,结合临床病理学指标进行分析。结果p27在卵巢癌的阳性表达率为37.0%(20/54),CD44V6的阳性表达率为42.6%(23/54)。p27在卵巢癌的临床Ⅲ￣Ⅳ期、低分化肿瘤和淋巴结转移阳性组的表达率分别为20.0%,12.0%和8.7%,显著低于临床Ⅰ￣Ⅱ期、高中分化肿瘤和淋巴结转移阴性组的表达率68.4%,58.6%和58.1%,P值分别为<0.05,<0.05和<0.01。CD44V6在卵巢癌的临床Ⅲ￣Ⅳ期和淋巴结转移阳性组的表达率分别为57.1%和73.9%,显著高于临床Ⅰ￣Ⅱ期和淋巴结阴性组的表达率15.8%和19.4%,P值分别为<0.05,<0.05。结论p27和CD44V6在卵巢癌的发生、发展中起着重要的调控作用。p27的缺失表达和CD44V6的高表达对卵巢癌的浸润、转移起重要作用,对分析卵巢癌的生物学行为和预后估计有重要意义。
Objective To study the expression and diagnostic value of p27 and CD44v6 in ovarian carcinomas, Methods 54 cases of ovarian carcinoma were examined by immunohistochemical two-step-system method for p27 and CD44v6. Results The positive rates of p27 and CD44v6 is 37.0 %（20/54）, 42.6 %（23/ 54） respectively. The positive rates of p27 is 20.0 %, 12.0 % and 8.7 % in clinic stage Ⅲ～Ⅳ, poorly differentiated tumors and lymphnode metastasis group compared with 68,4 %, 58.6 % and 58.1% in clinic stage Ⅰ—Ⅱ, well differentiated tumors and lymphnode negative group（P 〈 0.05, P 〈0.05 and P 〈0.01）, The positive rate of CD44v6 is 57.1%, 73.9 % in clinic stage Ⅲ -Ⅳ and lymphnode metastasis group compared with 15.8 %, 19.4 % in clinic stage Ⅰ -Ⅱ and lymphnode negative group （P 〈0.05, P 〈0.05. Conclusions The negative expression of p27 and the over expression of CD44v6 may play an important role in the development of ovarian carcinomas. Both of them were important in predicting the biological behavior and prognosis of ovarian carcinomas.
出处
《肿瘤研究与临床》
CAS
2006年第1期40-41,共2页
Cancer Research and Clinic
作者简介
张芸，女，主治医师，在读硕士研究生
